Physician profile
Kevin T Scripture
NPI 1700869179
$1,011.50
in general payments reported to CMS, 2019-2025
20 companies · $39.66 in 2025
The $39.66 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $14.19 · 2021: $78.49 · 2022: $281 · 2023: $65.94 · 2024: $256 · 2025: $39.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $295.65 | 2019-2024 | Clareon |
| Rxsight INC | $116.16 | 2022-2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $86.92 | 2022 | |
| Glaukos Corporation | $82.03 | 2020-2024 | Idose |
| Harrow Eye, LLC | $81.60 | 2024-2025 | Iheezo, Triesence |
| Genentech USA, INC. | $56.28 | 2024 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $34.43 | 2019-2021 | |
| Sight Sciences, INC. | $31.06 | 2019 | |
| Bausch & Lomb Americas INC. | $27.55 | 2022 | |
| Abbvie INC. | $24.26 | 2022 | |
| Sandoz INC. | $23.41 | 2025 | Cimerli |
| Johnson & Johnson Surgical Vision, INC. | $21.68 | 2024 | Tecnis Simplicity |
| Omeros Corporation | $19.32 | 2019 | |
| Rayner Intraocular Lenses Limited | $18.66 | 2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Coherus Oncology, INC. | $18.01 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $16.95 | 2021 | |
| Aerie Pharmaceuticals, INC. | $16.19 | 2021 | |
| Astellas Pharma US INC | $14.28 | 2024 | Izervay |
| Apellis Pharmaceuticals, INC. | $13.96 | 2023 | Syfovre |
| Novartis Pharmaceuticals Corporation | $13.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Scripture listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.